Posted by Michael Wonder on 14 Sep 2023
FDA approves new and updated indications for temozolomide under Project Renewal
14 September 2023 - Today, the FDA approved updated labelling for temozolomide (Temodar, Merck) under Project Renewal, an Oncology Center of Excellence initiative aimed at updating labelling information for older oncology drugs to ensure information is clinically meaningful and scientifically up-to-date.
This is the second drug to receive a labelling update under this pilot program.
